BidaskClub cut shares of Illumina (NASDAQ:ILMN) from a strong-buy rating to a buy rating in a report released on Thursday.
Other equities analysts also recently issued research reports about the company. Piper Jaffray Companies raised their target price on Illumina to $380.00 and gave the company an overweight rating in a research report on Tuesday, October 2nd. Cowen raised their target price on Illumina from $315.00 to $400.00 and gave the company a positive rating in a research report on Thursday, September 6th. Argus set a $372.00 target price on Illumina and gave the company a buy rating in a research report on Friday, August 10th. Morgan Stanley upgraded Illumina from an underweight rating to an equal weight rating and raised their target price for the company from $210.00 to $320.00 in a research report on Tuesday, August 7th. Finally, ValuEngine upgraded Illumina from a buy rating to a strong-buy rating in a research report on Tuesday, July 31st. Four equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Illumina presently has an average rating of Buy and a consensus price target of $322.56.
Shares of ILMN opened at $329.52 on Thursday. The company has a current ratio of 2.74, a quick ratio of 2.44 and a debt-to-equity ratio of 0.22. Illumina has a 12 month low of $198.21 and a 12 month high of $372.61. The company has a market capitalization of $53.96 billion, a price-to-earnings ratio of 82.38, a price-to-earnings-growth ratio of 3.04 and a beta of 0.97.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, July 30th. The life sciences company reported $1.43 EPS for the quarter, beating the consensus estimate of $1.11 by $0.32. Illumina had a return on equity of 26.64% and a net margin of 20.88%. The company had revenue of $830.00 million for the quarter, compared to analyst estimates of $786.88 million. During the same period last year, the company earned $0.82 earnings per share. Illumina’s quarterly revenue was up 25.4% compared to the same quarter last year. Research analysts anticipate that Illumina will post 5.46 earnings per share for the current year.
In related news, insider Francis A. Desouza sold 2,100 shares of Illumina stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $369.61, for a total transaction of $776,181.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Robert S. Epstein sold 500 shares of Illumina stock in a transaction that occurred on Monday, July 23rd. The stock was sold at an average price of $311.15, for a total value of $155,575.00. Following the transaction, the director now owns 6,139 shares in the company, valued at approximately $1,910,149.85. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,983 shares of company stock worth $16,679,124. 0.54% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in ILMN. Kaizen Advisory LLC lifted its position in Illumina by 161.0% during the second quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock worth $103,000 after buying an additional 227 shares in the last quarter. Moneta Group Investment Advisors LLC lifted its position in Illumina by 2,670.0% during the second quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock worth $107,000 after buying an additional 9,345 shares in the last quarter. Sun Life Financial INC lifted its position in Illumina by 152.5% during the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock worth $111,000 after buying an additional 241 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in Illumina by 3,192.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock worth $120,000 after buying an additional 415 shares in the last quarter. Finally, Hall Laurie J Trustee lifted its position in Illumina by 189.5% during the second quarter. Hall Laurie J Trustee now owns 550 shares of the life sciences company’s stock worth $154,000 after buying an additional 360 shares in the last quarter. Hedge funds and other institutional investors own 89.84% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: Diversification
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.